Get the Stockscreener App
2.76
3.16%
-0.09
After Hours:
2.76
Poseida Therapeutics Inc stock is currently priced at $2.76, with a 24-hour trading volume of 97,719.
It has seen a -3.16% decreased in the last 24 hours and a -5.48% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.82 pivot point. If it approaches the $2.69 support level, significant changes may occur.
Previous Close:
$2.85
Open:
$2.79
24h Volume:
97,719
Market Cap:
$267.60M
Revenue:
$64.70M
Net Income/Loss:
$-123.43M
P/E Ratio:
-11.50
EPS:
-0.24
Net Cash Flow:
$-95.23M
1W Performance:
+2.60%
1M Performance:
-5.48%
6M Performance:
-9.21%
1Y Performance:
+14.52%
1D Range:
$2.70
$2.82
52W Range:
$1.54
$4.27
Poseida Therapeutics Inc Stock (PSTX) Company Profile
Name
Poseida Therapeutics Inc
Sector
Industry
Phone
858-779-3100
Address
4242 Campus Point Court, Suite 700, San Diego
Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Initiated | H.C. Wainwright | Buy |
| Jan-07-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Aug-04-20 | Initiated | BofA Securities | Buy |
| Aug-04-20 | Initiated | Piper Sandler | Overweight |
| Aug-04-20 | Initiated | William Blair | Outperform |
View All
Poseida Therapeutics Inc Stock (PSTX) Latest News
Cantor Fitzgerald L. P. Purchases New Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Defense World
Reviewing Poseida Therapeutics (NASDAQ:PSTX) and Biogen (NASDAQ:BIIB) - Defense World
Defense World
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders - Lelezard
Lelezard
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders - The Malaysian Reserve
The Malaysian Reserve
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders - Marketscreener.com
Marketscreener.com
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders - Longview News-Journal
Longview News-Journal
Poseida Therapeutics Inc Stock (PSTX) Financials Data
Poseida Therapeutics Inc (PSTX) Revenue 2024
PSTX reported a revenue (TTM) of $64.70 million for the quarter ending December 31, 2023, a -50.42% decline year-over-year.
Poseida Therapeutics Inc (PSTX) Net Income 2024
PSTX net income (TTM) was -$123.43 million for the quarter ending December 31, 2023, a -92.85% decrease year-over-year.
Poseida Therapeutics Inc (PSTX) Cash Flow 2024
PSTX recorded a free cash flow (TTM) of -$95.23 million for the quarter ending December 31, 2023, a -210.25% decrease year-over-year.
Poseida Therapeutics Inc (PSTX) Earnings per Share 2024
PSTX earnings per share (TTM) was -$1.38 for the quarter ending December 31, 2023, a -26.61% decline year-over-year.
About Poseida Therapeutics Inc
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.
0.87%
0.21%
Cap:
|
Volume (24h):